https://www.live-feeds.com/feed/godzilla-of-weight-loss-drugs-could-provide-other-important-health-benefitsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/godzilla-of-weight-loss-drugs-could-provide-other-important-health-benefitshttps://www.live-feeds.com/feed/godzilla-of-weight-loss-drugs-could-provide-other-important-health-benefits#u104285Mon, 05 Oct 2026 23:07:10 +0000Retatrutide, an experimental triple-agonist drug from Eli Lilly, has demonstrated the ability to reduce body weight by up to 25% in trials. The medication targets three hormone pathways: GLP-1, GIP, and glucagon. In addition to weight reduction, phase 3 trial data indicates the drug improves blood sugar levels and reduces inflammation in adults with obesity and type 2 diabetes. While not yet approved by any regulatory agency, the drug is described as a potential new high-water mark for obesity treatments due to its multi-hormone mechanism.Why it mattersMost existing weight-loss drugs like Wego